CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tested a new drug (AZD8186) combined with chemotherapy (docetaxel) in 23 people with advanced solid tumors that have certain gene mutations (PTEN or PIK3CB). The main goals were to find the best dose and check for side effects. The study was completed, but …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New combo therapy shows promise for Hard-to-Treat prostate cancer
Disease control CompletedThis study tested whether adding precise, high-dose radiation (SBRT) to the drug apalutamide helps control prostate cancer that no longer responds to standard hormone therapy and has spread to a few spots. Twenty-six men with castration-resistant prostate cancer participated. The…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Hormone combo shows promise against resistant prostate cancer
Disease control CompletedThis study tested a new combination treatment for men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The treatment uses testosterone (given as shots) along with a drug called olaparib, which blocks cancer cells from repairing damage. …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
New hope for tough prostate cancer: drug cocktail shows promise in small trial
Disease control CompletedThis study tested a combination of two targeted antibodies (pertuzumab and trastuzumab) plus a chemotherapy drug (enzalutamide) in 7 men with advanced prostate cancer that had spread and stopped responding to standard hormone treatments. The goal was to see if the combo could shr…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:38 UTC